-
1Academic Journal
Συγγραφείς: A. A. Naumenko, I. S. Preobrazhenskaya, А. А. Науменко, И. С. Преображенская
Συνεισφορές: Мерц Фарма, ООО
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 10, No 4 (2018); 81-87 ; Неврология, нейропсихиатрия, психосоматика; Vol 10, No 4 (2018); 81-87 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2018-4
Θεματικοί όροι: когнитивно-моторный тренинг, vascular cognitive impairment, dementia, moderate cognitive impairment, pathogenetic therapy, basic symptomatic therapy, NMDA receptor antagonists, acatinol, acetylcholinesterase inhibitors, non-drug treatments, cognitive and motor training, сосудистые когнитивные нарушения, деменция, умеренные когнитивные нарушения, патогенетическая терапия, базисная симптоматическая терапия, антагонисты NMDA-рецепторов, акатинол, ингибиторы ацетилхолинэстеразы, нелекарственные методы лечения
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1001/816; Petersen RC, Stevens JC, Ganguli M, et al. Mild cognitive impairment (an evidence-based review). Neurology. 2001 May 8;56(9):1133-42.; Petersen RC. Mild cognitive impairment as a diagnostic entity. JIntern Med. 2004 Sep;256(3): 183-94.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 106 с.; Парфенов ВА, Неверовский ДВ. Ведение пациентов с дисциркуляторной энцефалопатией в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2015; 7(1):37-42. doi:10.14412/2074-2711-2015-1-37-42; Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12.; Kivipelto M, Helkala EL, Laakso M, et al. Middle life vascular risk factors and Alzheimer’s disease in later life: longitudinal population based study. BMJ. 2001 Jun 16;322(7300):1447-51.; Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. In: Rockwood K, Gauthier S, editors. Dementia therapeutic research. London a New York: Taylor a Francis; 2006. P. 189-212.; Iqbal K, Winblad B, Nishumura T, et al, editors. Alzheimer's disease: biology, diagnosis and therapeutics. J. Willey and sons; 1997. 831 p.; Преображенская ИС. Постинсультные когнитивные расстройства: причины, клинические проявления, лечение. Фарматека. 2013;(9):49-53. [Preobrazhenskaya IS. Poststroke cognitive disorders: causes, clinical manifestations, treatment. Farmateka. 2013;(9):49-53. (In Russ.)].; Barba R, Castro MD, del Mar Morin M, et al. Prestroke dementia. Cerebrovasc Dis. 2001;11(3):216-24.; Hachinski V. Vascular dementia: radical redefinition. In: Carlson LA, Gottfries SG; Winblad B, editors. Vascular dementia: etiology, pathogenesis and clinical aspects. S. Karger; 1994. P. 2-4.; Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi:10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.; Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. Sci Rep. 2016 Feb 15;6:20873. doi:10.1038/srep20873.; O’Brien J, Ames D, Gustafson L, et al, editors. Cerebrovascular disease, cognitive impairment and dementia. Second edition. Martin Dunitz; 2004.; Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to cognitive impairment and dementia: A Statement for healthcare Professionals from the American Heart Association / American Stroke Association. Stroke. 2011 Sep;42(9):2672-713. doi:10.1161/ STR.0b013e3182299496. Epub 2011 Jul 21.; Парфенов ВА. Профилактика болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2011;3(3):8-13.; Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004 Jan;128(1):32-8.; Hulette CM. Brain banking in the United States. JNeuropathol Exp Neurol. 2003 Jul; 62(7):715-22.; Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003 Apr;60(4):569-75.; Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35.; Kim GH, Lee JH, Seo SW, et al. Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiol Aging. 2015 Jan;36(1):485-91. doi:10.1016/j.neurobiolag-ing.2014.08.009. Epub 2014 Sep 28.; Захаров ВВ. Медикаментозная терапия в восстановительном периоде инсульта. Фар-матека. 2015;(9):80-7.; Butefisch CM. Plasticity in the human cerebral cortex: lessons from the normal brain and from stroke. Neuroscientist. 2004 Apr;10(2):163-73.; L0mo T. The discovery of long-term potentiation. Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):617-20.; Ziemann U, Muellbacher W, Hallett M, Cohen LG. Modulation of practice-dependent plasticity in human motor cortex. Brain. 2001 Jun;124(Pt 6):1171-81.; Захаров ВВ. Глутаматергическая терапия в восстановительном периоде после ишемического инсульта. Эффективная фармакотерапия. Неврология. 2014;(4):6-16.; Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin Interv Aging. 2009;4:367-77. Epub 2009 Oct 12.; Areosa Sastre A, Sheriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154.; Orgogozo JM, Rigaud AS, Sto ffler A, et al. Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia a Randomized, Placebo-Controlled Trial (MMM 300). Stroke. 2002 Jul;33(7):1834-9.; Wilcock G, Mo bius HJ, Sto ffler A; MMM 500 group. A double-blind, placebo-controlled multicenter study of Memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305.; Левин ОС, Юнищенко НА, Дударова МА. Эффективность акатинола мемантина при умеренно выраженном когнитивном расстройстве. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;(7):36-42.; Яхно НН, Преображенская ИС, Захаров ВВ, Мхитарян ЭА. Эффективность мемантина у пациентов с недементными когнитивными расстройствами. Результаты многоцентрового клинического наблюдения. Неврологический журнал. 2010;15(2): 52-8.; Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD005562. doi:10.1002/14651858.CD005562.pub2.; Martin M, Clare L, Altgassen AM, et al. Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev. 2011 Jan 19; (1):CD006220. doi:10.1002/14651858.CD006220.pub2.; Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2015 Apr 22;(4):CD005381. doi:10.1002/14651858.CD005381.pub4.; Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct; 43-44:38-53. doi:10.1016/j.mam.2015.06.003. Epub 2015 Jun 10.; Науменко АА, Громова ДО, Преображенская ИС. Когнитивный тренинг и реабилитация пациентов с когнитивными нарушениями. Доктор. Ру. 2017;(11):31-8.; Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi:10.1001/arch-neurol.2009.307.; Schmidt W, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013; 35(4):303-12. doi:10.1159/000347061. Epub 2013 Apr 10.; Bherer L. Cognitive plasticity in older adults: effects of cognitive training and physical exercise. Ann N YAcad Sci. 2015 Mar;1337:1-6. doi:10.1111/nyas.12682.; Bherer L, Kramer AF, Peterson MS, et al. Transfer effects in task-set cost and dual-task cost after dual-task training in older and younger adults: further evidence for cognitive plasticity in attentional control in late adulthood. Exp Aging Res. 2008 Jul-Sep;34(3): 188-219. doi:10.1080/03610730802070068.; Kolb B, Gibb R. Principles of neuroplasticity and behavior. In: Stuss D, Winocur G, Robertson I, editors. Cognitive neurorehabilitation: Evidence and Application. New York: Cambridge University Press; 2008. P. 6-21.; Wilson RS, Scherr PA, Schneider JA, et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology. 2007 Nov 13; 69(20):1911-20. Epub 2007 Jun 27.; Wada M, Noda Y, Shinagawa S, et al. Effect of Education on Alzheimer’s Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A CrossSectional Study. JAlzheimers Dis. 2018;63(2): 861-869. doi:10.3233/JAD-171168.; Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol. 2011 Jun;68(6):743-52. doi:10.1001/archneurol.2011.125.; Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Arch Neurol. 2011 Jun; 68(6):743-52. doi:10.1001/archneurol.2011.125.; Morris MC, Evans DA, Tangney CC, et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology. 2006 Oct 24;67(8):1370-6.; Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. John Wiley & Sons; 2007. P. 356-60.
-
2Academic Journal
Συγγραφείς: A. A. Naumenko, D. O. Gromova, N. V. Trofimova, I. S. Preobrazhenskaya, А. А. Науменко, Д. О. Громова, Н. В. Трофимова, И. А. Преображенская
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 8, No 4 (2016); 91-97 ; Неврология, нейропсихиатрия, психосоматика; Vol 8, No 4 (2016); 91-97 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2016-4
Θεματικοί όροι: когнитивно-моторный тренинг, cerebral amyloidosis, basic symptomatic treatment, central acetylcholinesterase inhibitors, NMDA receptor blockers, akatinol memantine, gantenerumab, nootropic therapy, cerebrolysin, non-drug exposures, cognitive-motor training, церебральный амилоидоз, базисное симптоматическое лечение, ингибиторы центральной ацетилхолинэстеразы, блокаторы NMDA-рецепторов, акатинол мемантин, гантенерумаб, нооторопная терапия, церебролизин, нелекарственные методы воздействия
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/680/619; Гаврилова СИ, Федорова ЯБ, Колыхалов ИВ и др. Терапевтический потенциал Церебролизина в превентивной терапии болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;(8): 24-9. [Gavrilova SI, Fedorova YaB, Kolykhalov IV, et al. The therapeutic potential of Cerebrolysin in the preventative treatment of Alzheimer's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;(8):24-9. (In Russ.)].; Гусев ЕИ, Гехт АБ, Белоусов ЮБ и др. Клинические и фармакоэкономические особенности применения Церебролизина в восстановительном лечении ишемического инсульта. Журнал неврологии и психиатрии им. С.С.Корсакова. 2007;(10):26-33. [Gusev EI, Gekht AB, Belousov YuB i dr. Clinical and pharmacoeconomic peculiarities of application of Cerebrolysin in rehabilitation of ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;(10):26-33. (In Russ.)].; Захаров ВВ, Яхно НН. Нарушения памяти. Москва: ГЭОТАР-Медиа; 2001. 160 с. [Zakharov VV, Yakhno NN. Narusheniya pamyati [Memory impairments]. Moscow: GEOTAR-Media; 2001. 160 p.]; Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi:10.1517/14712598.2011.578573. Epub 2011 Apr 20.; Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции. Руководство для врачей. 3-е издание. Москва: МЕДпресс-информ; 2011. С. 53-75. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachei [Dementia. A guide for physicians]. 3rd edition. Moscow: MEDpress-inform; 2011. P. 53-75.]; Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007 Feb 13;68(7):501-8. Epub 2006 Oct 25.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 224 с. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Remedium; 2014. 224 p.]; Преображенская ИС, Громова ДО. Некоторые аспекты терапии нейродегенеративных деменций. Медицинский совет. 2014;(10):36-42. [Preobrazhenskaya IS, Gromova DO. Some aspects of the therapy of neurodegenerative dementia. Meditsinskii sovet. 2014;(10):36-42. (In Russ.)].; Brickman AM, Siedlecki KL, Stern Y. Cognitive and Brain reserve. In: Depp CA, Jeste DV, editors. Successful Cognitive and Emotional Aging. Arlington: American Psychiatric Publishing, Inc; 2010. P. 157-72.; Erickson KI, Colcombe SJ, Wadhwa R, et al. Training-induced plasticity in older adults: effects of training on hemispheric asymmetry. Neurobiol Aging. 2007 Feb;28(2):272-83. Epub 2006 Feb 9.; Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol. 2001 Apr;49(4):433-42.; Dickerson BC, Goncharova I, SullivanMP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001 Sep-Oct;22(5): 747-54.; Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRImeasures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002 Apr 23;58(8):1188-96.; Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluidregistered serial MRI. Proc Natl Acad Sci USA. 2002 Apr 2;99(7):4703-7.; Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-59.; Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006213. doi:10.1101/cshperspect.a006213.; Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan;9(1):119-28. doi:10.1016/S1474-4422(09)70299-6.; Whitwell JL. Longitudinal imaging: change and causality. Curr Opin Neurol. 2008 Aug;21(4):410-6. doi:10.1097/WCO.0b013e32830719d4.; Toyn JH, Rowley A, Matsuoka Y, et al. γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease? Int JAlzheimers Dis. 2013;2013:849128. doi:10.1155/2013/849128. Epub 2013 Apr 18.; Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi:10.1517/14712598.2010.493872.; Novakovic D, Feligioni M, Scaccianoce S, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi:10.2147/DDDT.S53401.eCollection 2013.; Vellas B, Carrillo MC, Sampaio C, et al; EU/US/CTAD Task Force Members. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul;9(4):438-44. doi:10.1016/j.jalz.2013.03.007.; Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 2008 Dec 24;28(52):14156-64. doi:10.1523/JNEUROSCI.4147-08.2008.; Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012 Feb;69(2):198-207. doi:10.1001/archneurol.2011.1538.Epub2011 Oct 10.; Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002 May;1(1):3.; Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004 Oct;10(10):1055-63.; Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008 Mar 4;148(5):370-8.; Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007 Jul 24;69(4 Suppl 1):S4-9.; Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol. 2006 Jan;13(1):43-54.; Rockenstein E, Adame A, Mante M, et al. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm (Vienna). 2005 Feb;112(2):269-82. Epub 2004 Jul 7.; Rockenstein E, Torrance M, Mante M, et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 2006 May 15;83(7): 1252-61.; Gauthier S, ProaЦo JV, Jia J, et al. Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. doi:10.1159/000377672. Epub 2015 Mar 26.; Wey ZH, He QB, Wang H, et al. Metaanalysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm (Vienna). 2007;114(5):629-34. Epub 2007 Feb 23.; Weiner MW. Commentary on «Diagnosis of Alzheimer's disease: two decades of progress.» Central role of technology in the treatment and prevention of Alzheimer's disease. Alzheimers Dement. 2005 Oct;1(2):112-3.; Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults a meta-analytic study. Psychol Sci. 2003 Mar; 14(2):125-30.; Gates N, Fiatarone Singh MA, Sachdev PS, Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. Am J Geriatr Psychiatry. 2013 Nov;21(11):1086-97. doi:10.1016/j.jagp.2013.02.018. Epub 2013 Jul 3.; Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct;43-44: 38-53. doi:10.1016/j.mam.2015.06.003.Epub 2015 Jun 10.; Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi:10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.; Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. 4th ed. JohnWiley & Sons; 2007. P. 356-60.; Yates LA, Orrell M, Spector A, Orgeta V. Service users' involvement in the development of individual Cognitive Stimulation Therapy (iCST) for dementia: a qualitative study. BMC Geriatr. 2015 Feb 6;15:4. doi:10.1186/s12877-015-0004-5.; Boripuntakul S, Kothan S, Methapatara P, et al. Short-Term Effects of Cognitive Training Program for Individuals with Amnestic Mild Cognitive Impairment: a Pilot Study. 2nd ed. Taylor & Francis; 2012. P. 138-49.; van Paasschen J, Clare L, Yuen KS, et al. Cognitive rehabilitation changesmemory-related brain activity in people with Alzheimer disease. Neurorehabil Neural Repair. 2013 Jun;27(5):448-59. doi:10.1177/1545968312471902. Epub 2013 Jan 31.; Belleville S, Bherer L. Biomarkers of cognitive training effects in aging. Curr Transl Geriatr Exp Gerontol Rep. 2012 Apr 19;1(2): 104-110. Print 2012 Jun.; Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi:10.1001/archneurol.2009.307.; Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnesticmild cognitive impairment: a randomized controlled trial. BMC Neurol. 2012 Oct 31;12:128. doi:10.1186/1471-2377-12-128.; Schmidt W1, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013;35(4):303-12. doi:10.1159/000347061. Epub 2013 Apr 10.